Navigation Links
ADVENTRX Announces ANX-514 Clinical Development Plan Affirmed by the FDA
Date:9/10/2007

roving any Section 505(b)(2) NDA; the potential for regulatory authorities to require additional preclinical work or other clinical requirements to support regulatory filings; patent and non- patent exclusivity covering docetaxel; the risk that ADVENTRX will be unable to raise sufficient capital to fund the projects necessary to meet its anticipated or stated goals and milestones, including funding the continued development of ANX-514; and other risks and uncertainties more fully described in ADVENTRX's press releases and periodic filings with the Securities and Exchange Commission. ADVENTRX's public filings with the Securities and Exchange Commission are available at http://www.sec.gov.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made. ADVENTRX does not intend to revise or update any forward-looking statement, including as set forth in this press release, to reflect events or circumstances arising after the date on which it was made.


'/>"/>
SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...ER TOLEDO recently announced that Dr. Dominique He...e of Process Analytical Technology (PAT) in Green ... 1, 2009. , (PRWEB) Novem...alytical Technology (PAT) in Green Chemistry and G...nalytical Technology (PAT) case studies will be pr...
(Date:11/19/2009)...Newswire-FirstCall/ -- Omeros Corporation (Nasdaq:...ts for the third quarter ended September 30, 2009....eros reported a net loss of $3.9 million, or $1.34...ion, or $2.54 per share, for the same period in 20...the Company reported a net loss of $15.5 million, ...
(Date:11/19/2009)...RNewswire-FirstCall/ -- NeoStem, Inc. (NYSE Amex: ...wing letter to its shareholders, discussing the Co... Biopharmaceuticals Holdings, Inc. (CHBP), an inte...ple,s Republic of China. The merger gives NeoStem ...utical Co. Ltd., CHBP,s primary operating subsidia...
(Date:11/19/2009)...any, November 19 MONITORING FORCE ...th, 2009 Flibanserin in the,indication treatment-r...,disease for orphan drug status designation with t...ced dyskinesia is a complication of the mainstay,t...den to some of those,affected, since it may be dis...
Breaking Biology Technology:Process Analytical Technology (PAT) in Green Chemistry and Green Engineering 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 3MONITORING FORCE GmbH Requests Acknowledgment of Flibanserin as "Orphan Drug" 2
...usiness venture of Mike Strand in Eau Claire and a...an competition, has landed $250,000 from the Chip...ion, formerly Online Kiosks, has a plan to put vid...ople wait for appointments. After reaching the sta...e emerging growth category at Eau Claire Area Econ...
... Area Technical College,s Network Security Specia... viruses, worms and other threats to computer syst...the National Security Agency,s Committee on Natio... the state and 124 nationwide to carry the high-le...m precisely to what the NSA wishes students to be ...
...mbleGen Systems Inc. closed its latest, $8.2 mil...e venture funding to $50 million, the company said... Its microarrays, basically slides that can have t...anged in a grid, allow scientists and companies to..., , Cargill Ventures of Minneapolis, Minnesota, a...
Other Biology Technology:
(Date:11/23/2009)...hon Institute for Child Health Research has found ...sumption in pregnancy affects child behaviour in d...ed online in the international journal Addiction ...s was drawn from a random sample of more than 2000...s after the baby,s delivery, and were then followe...
(Date:11/23/2009)...erman . , Not just birds, but also a few spe...rchers at Princeton University in the U.S. and at ...zell, Germany studied the migratory behaviour of t...espertilionidae" with the help of mathematical mod... as well as long distances of various kinds of bat...
(Date:11/22/2009)...on can increase the likelihood of immune complicat...ernational team of researchers reports in the Nove... When the gene, called UGT2B17, is missing from th...ransplants have a significantly greater risk of a ...ease, in which immune cells from the donor attack ...
Breaking Biology News(10 mins):New study links alcohol in pregnancy to child behavior problems 2We're off then: The evolution of bat migration 2Gene mismatch influences success of bone marrow transplants 2Gene mismatch influences success of bone marrow transplants 3Gene mismatch influences success of bone marrow transplants 4Call for Proposals for Partners Investing in Nursings Future 57855 1Call for Proposals for Partners Investing in Nursings Future 57855 2Many Teens Circumvent Tanning Bed Laws 57851 1Many Teens Circumvent Tanning Bed Laws 57851 2Many Teens Circumvent Tanning Bed Laws 57851 3Secretary Shinseki Announces Progress on 241 4 Billion in Recovery Act Spending 57847 1Secretary Shinseki Announces Progress on 241 4 Billion in Recovery Act Spending 57847 2
... 1909, while harvesting a typical corn crop (Zea m...o unusual that it was initially believed to be a n...aside as a curiosity" and the specimen was designa...ny branches"). Due to the alteration of a single g...sel of the plant were more highly branched than us...
...x days is all it takes for a common, non-disease-c...d squamous cell cancer cells in laboratory culture...earchers. , "Our results suggest that adeno-assoc...ity of the population but has no known ill effects...effect on healthy cells," said Craig Meyers, Ph.D....
...ditor : The open access Public Library of Science ...os where you can see cells moving, be sure to chec...se, added by me. , Biologists have a new tool to...ing tissue. , Called two-photon laser-scanning mi...ic difference between the random wanderings of imm...
Other Biology News:$6.5 Million Grant for Microarray Center at Yale School of Medicine 2Study: Harmless virus kills some cancers 2Study: Harmless virus kills some cancers 3New tool reveals secrets of migrating cells 2New tool reveals secrets of migrating cells 3New tool reveals secrets of migrating cells 4New tool reveals secrets of migrating cells 5
...axy LIMS, Sophisticated Bioinformatics , Proprieta...entists ,We offer individual sample sequencing of...r single or double strand publication quality. Pr....3 to 7 kilobytes long. Universal or custom prime...
FDA-Submission Quality DNA Sequencing from Seqwright
Full-Length "Primer Walk" Sequencing from Seqwright
...no terminus) XAB2 (XPA-binding protein 2) was fir...munoprecipitation experiments have also demonstrat...scription-coupled repair-specific proteins CSA and...tion experiments with XAB2 antibodies resulted in ...
Biology Products: